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The mast cell is a member of the immune system having a basic role in al-
lergic (anaphylactic) reactions. However, it contains, synthesizes, stores and secretes 
lots of substances, which initiates other reactions or participates in them. These are 
in connection with the deterioration of tissue correlation, as malignant tumors, an-
giogenesis, wound healing, pregnancy and different pathological conditions. In ad-
dition – as other members of the immune system – mast cells can synthesize, store 
and secrete hormones characteristic to the endocrine glands and can transport them 
to the site of requirement (packed transport), or produce and employ them locally. 
The effect of mast cells is controversial and frequently dual, stimulatory or inhibi-
tory to the same organ or process. This is likely due to the heterogeneity of the mast 
cells, in morphology and cell content alike and dependent on the actual condition of 
the targeted tissue. The cells are transported in an unmatured form by the blood 
circulation and are exposed to microenvironmental effects, which infl uence their 
maturation. Their enrichment around tumors suggested using them as targets for 
tumor therapy more than fi fty years ago (by the author), however, this idea lives its 
renaissance now. The review discusses the facts and ideas critically.
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Introduction
The mast cells had been recognized one and a half century ago by von 
Recklinghausen as granular cells in the mesentery of the frog, however later, in 
1878 Paul Ehrlich, who stained them with aniline-dyes, gave the mast cell name, 
as these cells were fi lled with metachromatically stained granules. At present, 
still these stains are used for histological demonstration or the alcian blue-sa-
franin method [1] which can give also information on the degree of maturation 
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[2–4]. The cells have a haemopoietic origin, as other members of the immune 
system however, the mast cells are transported in unmatured state to the mucosal 
or connective tissue places of different organs, where the process of maturation 
is taking place [5, 6].
The numerous substances settled in the granules and intergranularly were 
discovered gradually and at least the mast cells were classifi ed as immune cells, 
a special member of the immune network. Today the cells are registered as a main 
factor of allergic reaction, having receptors and reacting to IgE, synthesizing and 
secreting histamine. However, only a portion of biologically active molecules 
contained by them are used in allergic or anaphylactic reactions and the cells are 
enriched particularly in such locations which are in close contact with the exter-
nal environment (skin, lung, intestines) [7] as well, as in the area of different 
pathophysiological processes. In addition, now the other – not directly immuno-
logical – functions of the whole immune system are in the front line of investiga-
tions [8]. This can explain why the others, non-immunological functions of mast 
cells are also studied lately.
Mast cells and tumors
Already at the end of the nineteenth century Paul Ehrlich, the “father of 
immunology” observed and described in his Doctor Theses [9], that mast cells 
are accumulated around and sometimes inside malignant tumors. Since this time 
this observation has been verifi ed many times [10] and the role of tumor derived 
growth factors [11, 12], stem cell factor, tumor necrosis factor (TNF) and CXL12 
[13], in the attraction of mast cells also has been cleared [14]. Mast cells arrive 
very early to the site of tumorous proliferation and stay there – regulating the 
growth process – up to the end-phase [12]. However, though more than a century 
passed, the exact role of mast cells seems not to be clear and it is multifaceted. 
There are some cases when mast cells stimulate [15], in other cases inhibit the 
growth of tumors [14, 16]. This dual role can be explained to some extent by the 
huge number of materials contained (produced) and secreted by mast cells as 
well, as the differences between mast cells in morphology and function [10] and 
the differences between tumors.
The tumor-infl uencing biologically active components of mast cells
The granules of mast cells contain heparin, histamine and serotonin and 
various proteases. In addition other molecules are also present inside and extra-
granularly, as cytokines, leukotrienes, chemokines, prostaglandins and many 
 MAST CELL: A HOMEOSTATIC ASPECT 209
Acta Microbiologica et Immunologica Hungarica 62, 2015
growth factors [16, 17]. Parts of the molecules are releasing during degranulation 
together, however, there is a possibility of secretion by individual granules with-
out complete degranulation and also intra- or extragranular mediators selectively 
(peacemeal degranulation) [16–19]. It is believed that for the tumor promoting 
effects the secretion of molecules is needed without degranulation [16].
While heparan sulphate which has a polysaccharide backbone identical to 
heparin is present in practically all cells of mammals, heparin is synthesized 
solely in mast cells [20]. In the medical practice heparin is an anticoagulant. 
However, during degranulation of mast cells it enriches around the cells infl uenc-
ing the microenvironment as well, as the coagulation ability of the blood. Hepa-
rin (or heparan sulphate) infl uences cell division, infl uencing the number and 
velocity of mitoses as well, as the appearance of atypical forms [21, 22]. It inhib-
its histamine release from mast cells [23], stimulates migration of capillary en-
dothelial cells [24, 25] and proliferation of intestinal epithelial cells [26]. It also 
infl uences the angiogenesis and the immune system [27, 28]. It is needed for the 
storage of histamine and proteases in the mast cell granules [29].
It was demonstrated in some studies that heparin either inhibits [17] or 
enhances (15, 30) the tumorous proliferation [28]. In this latter case it assists in 
promoting blood-borne metastasis [31, 32], which is inhibited by anticoagulants 
[33]. It is justifi ed that the components of heparin, glucuronic acid and glucosa-
mine stimulate the growth of tumors [34, 35] and shorten the lifespan of the ani-
mals, without acting to the non-tumorous controls. The extreme accumulation of 
mast cells around the tumors sometimes means a poor prognosis [15, 17]. This 
was expressed in the negativity of the diagnostic agar binding reaction at the end 
stage of tumor bearing patients [36–39], caused by the extreme degranulation of 
mast cells and consequently the enrichment of heparin in blood. However, in 
other experiments the higher number of mast cells around the tumor was a fa-
vorable prognostic factor [40, 41].
The other main component of the granule, histamine is known at fi rst in 
connection with allergic and infl ammatory reactions. However, based on many 
data, it has important positive or negative infl uence to mitosis of healthy cells 
[42–45] depending on the cell type and experimental conditions. Histamine is 
present and secreted by each mast cell-type (MCTC, MCT and MCC). Data show 
that histamine, and the other components, serotonin and heparin are packed in 
the same granules [46]. However, there are two types of serotonin storage pro-
teins, one is membrane associated, the other is free [47]. Histamine can infl uence 
the behavior of tumors. This role is also dual, as tumor cells have H1, H2 and H4 
receptors and histamine enhances tumor growth acting to the H1 receptors and 
suppresses it through H2 and H4 [16]. In addition, histamine has a local immuno-
suppressive effect [48]. Studying hepatoma cell lines, in HuH-6 cell viability and 
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proliferation were hampered by it, while in HA22T/VGH cell proliferation in-
creased [49]. When lung cancer has been induced, histamine inhibited this, while 
it was tumorogenic in case of lung tumor cell lines [50]. In case of melanoma, 
histamine can effect positively or negatively, depending on its local concentration 
and the type of receptors present [51–53]. In case of colon cancer cells enhance-
ment of growth and proangiogenic effect was observed through H2 and H4 recep-
tors and cyclooxygenase (COX-2) was involved in the process [49, 54]. When 
protumorigenic effect is manifested (caused by the collaboration of histamine 
and heparin), this favors the formation of metastases [12, 55].
In addition to heparin and histamine, acid hydrolases are present in the 
mast cell granules which are secreted by or without degranulation. These are 
chymase, tryptase, beta-hexosaminidase beta-glucuronidase, beta-D-galatosi-
dase, and aryl sulphatase, ionically bound to heparin [56]. The heparin protein 
complex is bound to histamine [57]. Because of the presence of acid hydrolases, 
the granule is believed to be a modifi ed lysosome. In rodents the mucosal type 
mast cell can be differentiated histochemically (morphologically) from connec-
tive tissue mast cells. In human beings the basis of differentiation is the chymase 
or tryptase content [58]. Although about 50% of the total protein content in mast 
cells is the mass of proteases, their function is dubious in general and unknown 
in case of tumors [59, 60]. However, the fl ood of hydrolases is poured in a fully 
active form during degranulation and this must effect the microenvironment. 
Tryptase is not only a proteinase, but a specifi c growth factor for fi broblasts [61]. 
In addition metalloproteases are also present in mast cells and their secretion 
helps tumor cell proliferation, migration and metastasis formation, by the de-
struction of the tumor-controlling environment [62]. Tumor cells also have a col-
lagenolytic activity, which is stimulated by mast cells [63].
Cytokines and growth factors are also synthesized by mast cells, which 
has positive or negative effects on the tumorous proliferation depending on the 
state of tumor. The cytokines which have antitumor activity are IL-1, IL-2, IL-4, 
IL-6, IL-10 and IFN-gamma, while the tumor promoting growth factors are 
TNF-alpha, TGF-beta 1, FGF-2, VEGF, PDGF, IL-8, NGF and osteopontin [64–
66]. The mast cells also have membrane receptors for numerous cytokines and 
chemokines which help or inhibit the accumulation of cells [67].
Chemokines are also cytokines, with cell migration and attraction infl u-
encing effects. Mast cells are producing chemokines, as IL-8, CXCL1/GRO al-
pha, CXCL8, CXCL10/IP10, MCP-1 and RANTES [68–70]. They also have re-
ceptors for chemokines [71]. As tumors also secrete chemokines, their secretion 
attracts mast cells which accumulate in the environment of tumors.
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Angiogenic functions of mast cells
The tumor cells can proliferate at fi rst without vascularization, however, 
after exceeding 5 mm they require the ingrowth of vessels. This process is stimu-
lated or inhibited by substances secreted by the mast cells [72], which are the 
earliest cells infi ltrating the developing tumor [73]. The stimulators (pro angio-
genic factors) are the growth factors, CSF, NGF, PDGF, SCF, VEGF, IL-8, bFGF, 
TGF-beta, VPF, osteopontin, angiogenin and histamine [74–76], the inhibitor is 
protamin [77, 78]. Heparin has a dual role: in some cases it has stimulatory, in 
other cases inhibitory effects [24, 78–81]. The experimental results are some-
times contradictory, for example VEGF is one of the most potent angiogenic 
growth factor [31, 82], however, in lung cancer the number of mast cells correlate 
in the grade of angiogenesis independently of VEGF expression [81]. All of the 
anti-angiogenic factors act through the inhibition of mast cell products [83]. 
When mast cells infl uence tumor angiogenesis, remodelling blood vessels [84], it 
also determines the further fate of the tumor, helping or suppressing the migra-
tion of the tumor cells and by this, metastasis formation [85].
Mast cells and wound healing
Mast cells have an important role in wound healing [86], secreting growth 
factors and histamine alike [87]. However, excess or defi cit of mediators released 
could cause abnormal repair (of skin), with keloid or hypertrophic scar formation 
[88]. The results are contradictory, as some experiments demonstrate that mast 
cells are needed for wound tissue granulation, blood wessel formation and colla-
gen maturation [89, 90], while other experiments show that mast cells do not ex-
ert major infl uence to the proliferation of cells during healing [91]. In fetal life 
mast cells positively infl uence the scarless repair [92]. An increased number of 
mast cells can be found in fi brotic diseases – in contrast to normal healing – 
around blood vessels [93]. Mast cells have a role in remodelling the tissues: cell 
breakdown, repair and regeneration [94, 95]. In this process IL-33, released by 
the necrotic cells and recognized by the receptors of mast cells, has an important 
role [96]. Mast cell proteases have a role in tissue repair, promoting healing how-
ever, and mast cell overweight could be detrimental [97].
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Endocrine function of mast cells
Hormones produced and secreted by mast cells
In addition to the main granule components, the biogenic amine histamine 
and serotonin (which also have hormonal function), other signal molecules are 
present in mast cells. These are the hormones produced mainly by endocrine 
glands, however, mast cells – similarly to other immune cells – can produce, store 
and secrete them [8, 98]. Triioidothyronine (T3), adrenocorticotropic hormone 
(ACTH), chorionic gonadotropin (hCG), vascular endothelial growth factor 
(VEGF) [99] and endorphin were demonstrated immunohistochemically in rat 
mast cells [100–103]. At the same time the demonstration of insulin and epider-
mal growth factor was unsuccessful. The amount of the hormones was gender-
dependent, in most of cases higher in females [101]. Corticotropin releasing hor-
mone (CRH) and its relative, urocortin were also found in human mast cells 
[104]. The atrial natriuretic peptide (ANP) is produced, stored and secreted dur-
ing degranulation by rat peritoneal mast cells [105] and prostaglandins were also 
found [106–107]. A rat mast cell line synthesizes and releases melatonin [108]. 
Histamin and serotonin can be demonstrated not only in the granules, but also in 
the nucleus of mast cells as well, as ACTH and growth hormone [100, 109].
For the synthesis of histamine, histidine as basic molecule is needed. For 
the maturation of granule also histamine synthesis is required, this means that the 
action of Hdc gene must be present for granule maturation [110]. Hdc-knockout 
mice have less mast cells and altered morphology of mast cell granules [111]. This 
seems to be clear. However, in these animals the production of ACTH, T3 and 
endorphin is also touched [112]. A similar role of mast cell histamine was ob-
served in the case of parathyroid gland [113].
The hormone production, storage and secretion can be infl uenced by hor-
monal imprinting, when the effect of neonatal treatment with the hormone is 
manifested later in adults, changing the endocrine function of the mast cells 
[114]. Neonatal imprinting with a single dose of endorphin signifi cantly dimin-
ished the endorphin, serotonin and hCG content of adult’s mast cells [102] and 
imprinting at weaning also decreased the endorphin and serotonin content in 
adults [115].
Hormone receptors and hormonal regulation of mast cells
Not only hormones, but hormone receptors are present in mast cells. Using 
the transmission by these receptors, the hormone production, storage and secre-
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tion of mast cell hormones can be regulated. Thyrotropic hormone (TSH) infl u-
ences T3 concentration of mast cells similarly to the regulation of the same pro-
cess in the thyroid gland [116]. This can be explained by the presence of T3 
receptors in the cytoplasm and nucleus of mast cells [117]. In the thyroid gland 
the exocytosis (degranulation) of mast cells is synchronized with thyroid activity 
[118].
MT1 and MT2 melatonin receptors are also present in the plasma mem-
brane of mast cells [108]. By the transmission of them, the pineal gland can infl u-
ence the development and function of mast cells [119–121]. Mast cells can infl u-
ence the calcifi cation of the pineal gland [122].
The cells do not contain glucocorticoids, however, these hormones have 
inhibitory effects on degranulation and other forms of secretion [123], while sup-
press mast cell survival [123,124], reduce mast cell number in diabetic rats [125] 
and infl uence mast cell development [126]. Exogeneously given corticosterone is 
able to build into the components of mast cells [127,128]. The cells have estrogen, 
androgen and progesterone receptors alike [129–131] and the hormones, by the 
transmission of these receptors infl uence the maturation of mast cells and secre-
tion of the molecules [126, 132–134]. They also react to the hormones of the pin-
eal–thyroid–thymus system [135, 136]. Corticotropin releasing hormone (CRH) 
receptors are also present and VEGF secretion is promoted by CRH in mast cells 
[137]. In the ovarian complex 17-beta estradiol was the strongest degranulator of 
mast cells, however, luteinizing hormone (LH), follicle stimulating hormone 
(FSH) and TSH also showed this effect [138]. ACTH is a strong degranulator, too 
[139, 140].
The hormone of the parathyroid gland, parathormone (PTH) in vitro and in 
vivo stimulates mast cell degranulation [141]. It seems likely that the cells have a 
role in bone turnover and the increased number of mast cells is in connection 
with accelerated bone loss and the defi ciency with stimulated osteoblastic func-
tion [142]. PTH excess causes the increase of mast cells at the bone–bone marrow 
interface in case of elevated PTH level (hyperparathyreosis) [143].
Insulin infl uences (inhibits) mast cell degranulation and histamine release 
during diabetes [144] and it is hypothesized that mast cells are involved in insulin 
resistance and type 2 diabetes [145].
Stress is a general activator of the endocrine system and has a dual role to 
the immune system. By this, it activates the CRH-mast cell-histamine axis [146]. 
A perinatal stress – causing hormonal imprinting – durably elevates the ACTH 
level in mast cells of adult male rats [147].
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The sentinel function of mast cells
Mast cells have a sentinel function in innate and adaptive immunity, how-
ever they have similar role in pregnacy and pathophysiological conditions [148]. 
As the earliest defense cell, which contains and secretes a mass of biologically 
active materials during tumor formation or pregnacy, it also has a sentinel func-
tion [72]. Located under the epithelial surfaces, it is a sentinel in the case of bacte-
rial or parasitic infections as well, as sensing cell injury [96, 149].
Mast cells and pregnancy
A huge amount of mast cells are present in the uterus and the placenta. It 
was measured that the placenta contains 7.6×105 mast cells/g wet weight tissue 
[150] and these cells release histamine during degranulation. During pregnancy 
mast cell density is higher than in non-pregnant state [151]. The histamine (and 
serotonin) liberated from the uterine mast cells control cervical function [152] 
and infl uences the conractility of myometrium [153]. This latter is supported by 
in vitro experiments, when myometrial strips were studied [154]. It is suggested 
that mast cell histamine is important in normal ovulation and blastocyst implan-
tation [155], acting through histamine H1 receptors [156]. Mast cells also infl u-
ence early abortions, justifi ed by the enormous increase of mast cells of decidua 
(from 36.27 to 448.7/mm2) in this case [157]. It seems likely that this effect is 
controlled by secretion of cytokines. The mast cells could have a dual role in the 
reproductive system, as the early [157, 158] stage of pregnancy helps blastocyst 
implantation and blood fl ow regulation [155], however, later they can activate 
preterm delivery [159]. Their angiogenic effect is also important in case of the 
cervix [160].
Metabolic syndrome and other – non-immune – diseases
Mast cells have a signifi cant role in such metabolic syndromes as obesity 
and type 2 diabetes, as well as in insulin resistance [144, 145]. The white adipose 
tissue contains a large amount of mast cell precursor hemopoietic cells [161], in 
physiological and pathological conditions alike. The prostaglandins produced 
and secreted by mast cells induce adipocyte differentiation and can cause obesity 
[106]. The preadipocyte–adipocyte transformation is helped by mast cells [162]. 
In leptin-defi ciency induced obesity the epididymal fat showed a 20-fold increase 
and a 13-fold decrease of subcutaneous fat mast cell number and also a mast cell 
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increase in the lymph nodes [163]. Mast cell proteases, chymase and tryptase are 
risk factors for diabetes and the stabilization of mast cells decreases the chance to 
diabetes [164]. Mast cell function inhibitors can be a promising treatment of obe-
sity in the future [165].
Cardiovascular diseases are or can be promoted by mast cells [166, 167]. 
The mast cell-specifi c proteases have a role (in animal experiments) in the devel-
opment of atherosclerosis and aneurisms [168] and selective chymase and tryptase 
inhibitors have benefi cial effects in these cases. Mast cell stabilizers (anti-allergy 
medications) also decrease cardiovascular complications [169]. Not only the pro-
teinases have a role in the formation of atherosis plaques, but some growth fac-
tors, histamine and chemokines [170]. Alzheimer disease is among the patho-
logical states which are also infl uenced by mast cells [107, 171]. It is supposed that 
the protease of them generates the production of perivascular beta protein which 
aggregates into beta-amyloid deposits. In the gastrointestinal (GI) area mast cells 
are involved in increased gastric secretion, polyp formation and irritable bowel 
syndrome [172]. It seems to be likely that the central nervous system infl uences 
GI mast cells and vica versa [173, 174].
Conclusions
The immune system contains different cells which can differentiate be-
tween self and non-self and after recognition it destroyes the non-self, either this 
penetrates into the organism from outside (bacteria, viruses and parasites) or 
develops inside it. However, the cells of the immune system (lymphocytes, mono-
cyte-macrophage cells and mast cells) synthesize, store and secrete hormones, 
characteristic to the endocrine glands. Nevertheless, the cells of the endocrine 
glands are monoproducers, synthesizing one hormone, while the cells of the im-
mune system are polyproducers, synthesizing almost all amino-acid or polypep-
tide hormones, which were searched at all. The mast cell is an outstanding mem-
ber of this immunoendocrine system, as rich in hormones and hormone-like 
molecules (e.g. growth hormones, osteopontin, etc.) and in addition it also syn-
thesizes and secretes other biologically active and important substances, as hepa-
rin and proteolytic enzymes (chymase, tryptase), which are bound to each other 
in the granules and can be secreted together, or separately. This factory of bio-
logically active molecules is mobile and can transport the molecules ready for 
secretion to different places of the organism, where there is a requirement to them 
(packed transport) [8, 175]. The requirement is sensed by receptors present in the 
plasma membrane of mast cells, which are in a close contact with blood vessels. 
It seems likely that this is the reason why mast cells are among the fi rst cells, 
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which reach the developing tumors. The ability of packed transport (of hormones) 
is also a property of all immune cells, however, the mast cell is the largest factory, 
which transports the most molecules and which can fabricate the most active 
molecules locally. Although it was not tested that the locally secreted hormones 
infl uence the proliferation of tumors or not, this is theoretically not precluded. T3 
e.g. can infl uence cell proliferation [176, 177] and it is synthesized and secreted 
by mast cells.
At the lowest level of eukaryotic phylogeny the unicellular eukaryotes, as 
Tetrahymena, synthesize hormones, characteristic to mammals and able to com-
municate by the help of them [178, 179]. The cell is a polyproducer and also poly-
receiver, having receptors for the hormones, which are strenghtened after im-
printing [180]. While the primitive cells which accumulate to form the endocrine 
glands during the evolution, loose this multifaceted capacity, the immune cells 
(up to the mammals) keep this property, and fi rst of all the mast cells [181], which 
produce the fl ood of signal molecules and express a huge number of receptors, as 
it is in Tetrahymena [178]. These cells are very ancient, their ancestors can be 
found in Ciona intestinalis or Styela plicata, the origin of which can be deduced 
to at least 500 million years ago [182, 183].
Although mast cell is a member of the immun system, its functions are dif-
ferent from the other members. It does not participate directly in the recognition 
of non-self and does not destroy it, as it is done by lymphocytes and macrophag-
es. As an immune cell, it is participating fi rst of all in the allergic reactions, 
however, it sustains the tissue homeostasis, the healing processes after injury and 
helps in the remodelling of the destroyed tissue patterns. Considering that in our 
most present knowledge the immune system in general serves not only the recog-
nition and destruction of non-self, the prominent homeostatical role of mast cells 
is not surprising. However, if the fi rst recognized function of mast cell would 
have been this homeostatic one, it would be recorded as a special homeostasis 
controlling cell, which has also immune function, as one of its numerous proper-
ties.
Another speciality of mast cells is the presence of hormones in the nucleus. 
However, not all of the hormones produced by the mast cells themselves can be 
found, but histamine and serotonin, the main components of granules and ACTH 
as well, as growth hormone, are present, while T3, insulin and endorphin were 
not found. Other immune cell nucleus did not show this phenomenon, in these 
cells at most around the nucleus were hormones found [184]. It is not known 
whether the intranuclear hormones are the self-products of mast cells or they 
were taken up from the bood circulation. However, cytoplasmic or intranuclear 
receptors for these hormones are unknown. Also unknown is the function of the 
hormones in the nucleus.
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As it was told, the mast cells have a bone marrow origin [185], however, 
their maturation takes place in different lymphoid organs (at fi rst in the thymus) 
[186, 187] as well, as in different places of the organism, to where they are trans-
ported by the blood circulation [188, 189], which is not a passive transporter, as 
the serum helps the maturation of the cells [190]. The microenvironment also has 
a determining effect to them. KIT ligand, acting on the KIT receptor is the most 
important factor in the development of the cell [185], however, it seems likely that 
the environment evokes different types of mast cells, which is manifested e.g. in 
the chymase or tryptase overweight and in the different staining of the connec-
tive tissue mast cells (CTMC) and peritoneal mast cells [191]. CTMCs keep their 
proliferation potential after maturation, while mucosal mast cells lose it [185]. 
CTMCs and mucosal mast cells are located in different places, after transplanted 
together. However, in case of peritoneal mast cells, the large granule-stuffed cells 
are inactive, while the small (young) and medium-sized cells are active and can 
contact other cells (e.g. lymphocytes), which infl uences their behavior [192]. 
There are also differences in the receptivity and answer to hormones depending 
on the location, maturity and type of mast cells [137–139]. Considering the het-
erogeneity of the mast cell population [193, 194], it is very diffi cult to develop an 
uniform opinion about the functions of mast cells, without mentioning their type 
or localization. However, as the mast cells are mainly characterized by the me-
tachromatic staining of granules, theoretically also imaginable that the different 
members of the population in an organism are different cell types (containing 
heparin) with different functions. Due to it, the dual roles, which are present fre-
quently in connection of mast cell functions, can be explained.
As it was clearly seen that mast cells produce numerous substances, the 
question is, what is the primary, which induces the synthesis of others, or what is 
the organizer of granule formation. In experimental conditions histamine or sero-
tonin induces heparin formation, whilst heparin is not able to induce the forma-
tion of them [195]. Also, in cell-free model granule formation only takes place, if 
all components are present in a suitable ratio [196]. In vivo histamine synthesis is 
needed for the granule formation [110]. This means that histamin is the primary, 
which initiates heparin synthesis. In addition, as histamine can be released from 
the granule without degranulation something is needed to bind the heparin after 
that. This “something” is histone [197, 198], which also present in the granule and 
being a basic protein, can bind the acidic heparin. These scarce data show that 
there is a self-regulation inside the cell, in addition to the regulating function of 
microenvironment.
There is always a problem, whether the above listed properties are the spe-
cifi cities of mast cells, or other cells also have them, however, they were studied 
less, while mast cells were in the front of interest. When the hormones were 
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studied in the immune cells, practically all of them were found (except steroids) 
and from this point of view there was no difference among the different cells. 
There is a possibility that other members of the immune system contain the ma-
jority of materials found in mast cells, however, this was not studied or the results 
were not published. So, it must be cautious to declare their speciality in all of the 
functions or contents, however, some materials are characteristic to them. These 
are heparin (the molecule by which it can be found histochemically), histamine, 
and the protease enzymes. Considering the heterogeneity of the cells, we call 
mast cells all of the cells, which contain these components, and in the cytoplasm 
have metachromatically stained granular structures.
Most of the biologically active components of the mast cells are peptides 
and amino acid-like materials except heparin, which is a stranger, a polysaccha-
ride. It is composed of glucosamine and glucuronic acid. It is not known whether 
these two components of heparin are synthesized by the cell itself or are taken up 
from the milieu [199]. However, the tumor growth promoting effect of these mol-
ecules has been demonstrated [10, 34]. When the development of a malignant 
tumor started, mast cells accumulated around it, attracted by the factors secreted 
by the tumorous cells. It is likely that not specifi cally the tumor attracts the mast 
cells, but the breaking down of tissue correlation (harmony), as the mast cells are 
accumulating also in other places, where the tissue correlation is destroyed [200], 
e.g. in wound healing or pregnancy. The surrounding mast cells have a dual role 
on the development of the tumor, promoting or inhibiting it. Considering the huge 
number of materials present in mast cells, this controversial effect can be done by 
different substances secreted, or the same substance secreted in different periods 
of tumor development. If mast cells in the neighborhood of the tumor take up 
heparin or its components, concurring with the tumor, which also require them 
for the proliferation, this causes inhibition. In opposite, the degranulation of mast 
cells presents heparinoids for use.
It is an interesting question, why tumors secrete such substances, which 
attract mast cells, if these cells can be harmful to the organism, stimulating the 
growth and development of the tumor. One of the explanations could be that the 
malignant tumor is autonomous and by this activity it helps the propagation of 
malignancy. Another – and most likely – explanation is, that the accumulation of 
mast cells is provoked by the disturbance of local homeostasis, independent on its 
malignancy or benevolency. They “want” to restore the normal state, while such 
substances are also released which promote the tumorous proliferation. The situ-
ation is similar to the spontaneous action of immune cells, which offend the use-
ful transplanted tissue because of its nonselfness.
It is not dubious that mast cells have negative or positive infl uence on tumor 
development, however, there are no data on their effect on tumor formation. The 
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suppression of immunity promotes tumor formation, nevertheless, the role of 
mast cells in the process is unknown. Considering the role of mast cells in the 
restoration of tissue homeostasis, the effect of their blockade (e.g by psychosocial 
depression) to this process can be suspected, however, it was not studied.
More attention would be needed for the dual role also in other cases. Not 
only the tumorous proliferation destroyes the normal local homeostasis, but preg-
nancy too. It seems likely that this attracts a huge number of mast cells there. 
Considering the importance of this physiological process, relatively scarce data 
are at our disposal on the role of mast cells in the maintenance or rejection of the 
half-strange embryo. However, the present data point to this problem and call at-
tention to the possibility of prevention or treatment by infl uencing the behavior of 
mast cells.
At present, authors of numerous papers propose an attack against tumors 
by targeting the mast cells around or inside it [14, 41, 201–203]. It is mentioned as 
a new fi eld of treatment. However, this kind of therapy was proposed more than 
50 years ago and there were experiments which supported this possibility. The 
author of this paper proposed 1) the binding of cytostatics to a heparinoid trans-
porter which could help the accumulation of it around tumors, or 2) the binding 
of cytostatics to metachromatic dyes. Both methods were executed in animal 
experiments and resulted in very effective tumor destruction and life prolonga-
tion of tumor bearing animals [204–209]. Some of them were studied on human 
beings, with positive results [210]. In that time less was known on the role of mast 
cells in general. However, this line of tumor treatment or similar ones can be 
continued.
When I am writing this review paper, PubMed lists about 37,000, and 
Google shows 182,000 papers in which “mast cell” is found. This review contains 
210 citations. It was very diffi cult to select those papers which really represent the 
important functions of mast cells, or show exactly what diseases in which mast 
cells have decisive non-immune roles. There could be functions which are more 
important, than those of presently known, however, they were not studied in the 
absence of intention, or tools for doing it. Nevertheless, the paper shows what the 
main non-immune functions are of mast cells at present, and what the directions 
of research are. It also points to some almost forgotten data and ideas, which 
seem to be timely.
Considering the above mentioned facts and ideas, it can be accepted that 
mast cells are members of the immune system with strong heterogeneity and 
other – non-immune – functions. These functions seem to be as important, as the 
immune one. Although almost month after month new functions are recognized, 
sometimes the old functions are still uncertain and frequently controversial, ex-
cept their key role in allergy and anaphylaxis. As the study of non-immune func-
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tions of mast cells is in progress, also the therapeutic application of the new 
knowledge is hopeful.
References
1. Spicer, S. S.: A correlative study of the histochemical properties of rodent acid muco-
polysaccharides. J Histochem Cytochem 8, 18–35 (1960).
2. Csaba, G., Oláh, I.: Mechanism of the formation of mast cell granules, 8. Ultrastructure 
of model granules. Acta Biol Acad Sci Hung 23, 133–144 (1972).
3. Csaba, G., Forgács, A.: The ontogenesis of mast cells. Acta Biol Acad Sci Hung 22, 
423–430 (1971).
4. Csaba, G., Oláh, I.: Mechanism of the formation of mast cell granules I. Ultrastructural 
and histochemical study in a model consisting of living cells. Acta Biol Acad Sci Hung 
19, 347–362 (1968).
5. Yong, L. C.: The mast cell: Origin, morphology, distribution, and function. Exp Toxicol 
Pathol 49, 409–424 (1997).
6. Moon, T. C., St. Laurent, C. D., Morris, K. E., Marcet, C., Yoshimura, T., Sekar, Y., Be-
fus, A. D.: Advances in mast cell biology: New understanding of heterogeneity and func-
tion. Mucosal Immunology 3, 111–124 (2010).
7. Zhang, J., Shi, G. P.: Mast cells and metabolic syndrome. Biochem Biophys Acta 1822, 
14–20 (2012).
8. Csaba, G.: The immuno-endocrine system: Hormones, receptors and endocrine function 
of immune cells. The packed transport theory. Adv Neuroimm Biol 1, 71–85 (2011).
9. Ehrlich, P.: Beitrage zur Theorie und Praxis der Histologischen Farbung. Thesis, Leipzig 
University, 1878.
10. Csaba, G., Ács, T., Horváth, C., Mold, K.: Genesis and function of mast cells. Mast cell 
and plasmacyte reaction to induced, homologous and heterologous tumours. Br J Cancer 
15, 327–335 (1961).
11. Brzezinska-Blaszczyk, E., Pitrzak, A., Misiak-Tloczek, A. H.: Tumor necrosis factor 
(TNF) is a potent rat mast cell chemoattractant. J Interferon Cytokine Res 27, 911–919 
(2007).
12. Conti, P., Castellani, M. L., Kempuraj, D., Salini, V., Vecchiet, J., Teté, S., Mastrangelo, 
F., Perrella, A., DeLutiis, M. A., Tagen, M., Theoharides, T. C.: Role of mast cells in 
tumor growth. Ann Clin Lab Sci 37, 315–322 (2007).
13. Polajeva, J., Sjösten, A. M., Lager, N., Kastemar, M., Waem, I., Alafuzoff, I., Smits, A., 
Westermark, B., Pejler, G., Uhrbom, L., Tschogounova, E.: Mast cell accumulation in 
glioblastoma with a potential role for stem cell factor and chemokine CXCL 12. Plos 
One 6, e25222 (2011).
14. Groot Kormelink, T., Abudukelimu, A., Redegeld, F. A.: Mast cells as target in cancer 
therapy. Curr Pharm Des 15, 1868–1878 (2009).
15. Tóth-Jakatics, R., Jimi, S., Takebayashi, S., Kawamoto, N.: Cutaneous malignant mela-
noma: Correlation between neovascularisation and peritumoral accumulation of mast 
cells overexpressing vascular endothelial growth factors. Hum Pathol 31, 955–960 
(2000).
 MAST CELL: A HOMEOSTATIC ASPECT 221
Acta Microbiologica et Immunologica Hungarica 62, 2015
16. Theoharides, T. C., Alysandratos, K. D., Angelidou, A. A., Zhang, B.: Mast cells and 
tumor microenvironment. In Bagley R. G.: The Tumor Microenvironment, Cancer Drug 
Discovery and Development. Springer Science and Business Media, 2010, pp. 353–375.
17. Theoharides, T. C., Conti, P.: Mast cells: The Jekyll and Hyde of tumor growth. Trends 
Immunol 5, 235–242 (2004).
18. Dabbous, M. K., Walker, R., Haney, L., Carter, M. L., Nicolson, G. L., Woolley, D. E.: 
Mast cell and matrix degradation at sites of tumour invasion in rat mammary gland 
 adenocarcinoma. Br J Cancer 54, 459–465 (1986).
19. Theoharides, T. C., Bondy, P. K., Tsakalos, N. D., Askenase, P. W.: Differential release 
of serotonin and histamine from mast cells. Nature 297, 229–231 (1982).
20. Carlsson, P., Kjellén, L.: Heparin biosynthesis. Handb Exp Pharmacol 207, 23–41 (2012).
21. Csaba, G., Kapa, E., Mold, K., Törő, I.: On atypical mitoses in tissue culture after hepa-
rin therapy. Z Mikr Anat Forsch 67, 131–139 (1961).
22. Fedarko, N. S., Ishihara, M., Conrad, H. E.: Control of cell division in hepatoma cells by 
exogenous heparin sulphate proteoglycan. J Cell Physiol 139, 287–294 (1989).
23. Inase, N., Schreck, R. E., Lazarus, S. C.: Heparin inhibits histamine release from canine 
mast cells. Am J Physiol 264, L387–L390 (1993).
24. Azizkhan, R. G., Azizkhan, J. C., Zetter, B. R., Folkman, J.: Mast cell heparin stimulates 
migration of capillary endothelial cells in vitro. J Exp Med 152, 931–944 (1980).
25. Mitsi, M., Forsten-Williams, K., Gopalakrishnan, M., Nugent, M. A.: A catalytic role of 
heparin within the extracellular matrix. J Biol Chem 283, 34796–34807 (2008).
26. Flint, N., Cove, F. L., Evans, G. S.: Heparin stimulates the proliferation of intestinal epi-
thelial cells in primary culture. J Cell Sci 107, 401–411 (1994).
27. Tyrrell, J. D., Horne, A. P., Holme, K. R., Preuss, J. M., Page, C. P.: Heparin in infl am-
mation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 46, 
151–208 (1999).
28. Smorenburg, S. M., Van Noorden, C. J. F.: The complex effects of heparins on cancer 
progression and metastasis in experimental studies. Pharmacol Rev 53, 93–105 (2001).
29. Humphries, D. E., Wong, G. W., Friend, D. S., Gurish, M. F., Qiu, W. T., Huang, C., 
Sharpe, A. H., Stevens, R. L.: Heparin is essential for the storage of specifi c granule 
proteases in mast cells. Nature 400, 769–772 (1999).
30. Roche, W. R.: Mast cells and tumors. The specifi c enhancement of tumor proliferation 
in vitro. Am J Pathol 119, 57–64 (1985).
31. Ch’ng, S., Wallis, R. A., Yuan, L., Davis, P. F., Tan, S. T.: Mast cells and cutaneous ma-
lignancies. Mod Pathol 19, 149–159 (2006).
32. Kozlowski, E. O., Pavao, M. S.: Effect of sulfated glycosaminoglycans on tumor inva-
sion and metastasis. Front Biosci 3, 1541–1551 (2011).
33. Bobek, V., Kovarik, J.: Antitumor and antimetastatic effect of warfarin and heparins. 
Biomed Pharmacother 58, 213–219 (2004).
34. Csaba, G., Horváth, C., Ács, T.: Some new data concerning the biology of tumors. The 
effects of heparin and its components on tumour growth. Br J Cancer 14, 362–366 (1960).
35. Dimitriadou, V., Koutsilieris, M.: Mast cell-tumor cell interactions: For or against tu-
mour growth and metastasis? Anticancer Res 17, 1541–1549 (1997).
36. Csaba, G., Törő, I.: A new procedure for cancer diagnosis: The agar binding reaction. 
Z Krebsforsch 62, 481–494 (1958).
222 CSABA
Acta Microbiologica et Immunologica Hungarica 62, 2015
37. Csaba, G., Törő, I.: On the exact mechanism of the agar-binding reaction in a quantita-
tive method. Neoplasma 6, 366–382 (1959).
38. Káplár, Z., Kónya, Z., Szinnyai, M.: Use of Csaba-Törő’s agar fi xation reaction in the 
 diagnosis of gynecological cancer. Orv Hetil 100, 1771–1773 (1959).
39. Kleine, N., Obrecht, P., Brahms, A.: Research on the agar binding reaction of Csaba and 
Törő. Klin Wochenschr 40, 201–205 (1962).
40. della Rovere, F., Granata, A., Familiari, D., D’Arrigo, G., Mondello, B., Basile, G.: Mast 
cells in invasive ductal breast cancer: Different behavior in high and minimum hor-
mone-receptive cancers. Anticancer Res 27, 2465–2471 (2007).
41. Oldford, S. A., Marshall, J. S.: Mast cells as targets for immunotherapy of solid tumors. 
Mol Immunol 63, 113–124 (2015).
42. Harper, R. A., Flaxman, B. A.: Effect of pharmacologic agents on human keratinocyte 
mitosis in vitro. III. Inhibition by histamine and methylated analogs. J Invest Dermatol 
65, 400–403 (1975).
43. Tutton, P. J.: The infl uence of histamine on epithelial cell proliferation in the jejunum of 
the rat. Clin Exp Pharmacol Physiol 3, 369–373 (1976).
44. Franzén, L.: Further studies on the relationship between drug-induced mast-cell secre-
tion and local cell proliferation. Acta Pathol Microbiol Scand A 89, 57–62 (1981).
45. Norrby, K.: Intradermal mast-cell secretion causing cutaneous mitogenesis. Virechows 
Arch B 42, 263–269 (1983).
46. Wingren, U., Wasteson, A., Enerback, L.: Storage and turnover of histamine, 5-hydroxy-
triptamine and heparin in rat peritoneal mast cells in vivo. Int Arch Allergy Appl Im-
munol 70, 193–199 (1983).
47. Tamir, H., Theoharides, T. C., Gershon, M. D., Askenase, P. W.: Serotonin storage pools 
in basophil leukemia mast cells: Characterization of two types of serotonin binding pro-
tein and radioautograhic analysis of the intracellular distribution of [3H] serotonin. 
J Cell Biol 93, 638–647 (1982).
48. Reynolds, J. R., Akhter, J. A., Magarey, C. J., Schwartz, P. J., Adams, W. J., Morris, 
D. L.: Histamine in human breast cancer. Br J Surg 85, 538–541 (1998).
49. Lampiasi, N., Azzolina, A., Montalto, G., Cervello, M.: Histamine and spontaneously 
released mast cell granules affect cell growth of human hepatocellular carcinoma cells. 
Exp Mol Med 39, 284–294 (2007).
50. Stoyanov, E., Uddin, M., Mankuta, D., Dubinett, S. M., Levi-Schaffer, F.: Mast cells and 
histamine enhance the proliferation of non-small cell lung cancer cells. Lung Cancer 75, 
38–44 (2012).
51. Lázár-Molnár, E., Hegyesi, H., Pállinger, É., Kovács, P., Tóth, S., Fitzsimons, C., Cricco, 
G., Martin, G., Bergoc, R., Darvas, Z., Rivera, E. S., Falus, A.: Inhibition of human pri-
mary melanoma cell proliferaton by histamine is enhanced by interleukin-6. Exp J Clin 
Invest 32, 743–749 (2002).
52. Falus, A., Hegyesi, H., Lázár-Molnár, E., Pós, Z., László, V., Darvas, Z.: Paracrine and 
autocrine interactions in melanoma: Histamine is a relevant player in local regulation. 
Trends Immunol 22, 648–652 (2001).
53. Medina, V. A., Massari, N. A., Cricco, G. P., Martin, G. A., Bergoc, R. M., Rivera, E. S.: 
Involvement of hydrogen peroxide in histamine-induced modulation of WM35 human 
malignant melanoma cell proliferation. Free Radic Biol Med 46, 1510–1515 (2009).
54. Chianchi, F., Cortesini, C., Schiavone, N., Perna, F., Magnelli, L., Fanti, E., Bani, D., 
Messerini, L., Fabbroni, V., Perigli, G., Capaccioli, S., Masini, L.: The role of cyclooxy-
 MAST CELL: A HOMEOSTATIC ASPECT 223
Acta Microbiologica et Immunologica Hungarica 62, 2015
genase-2 in mediating the effects of histamine on cell proliferation and vascular en-
dothelial growth factor production in colorectal cancer. Clin Cancer Res 11, 6807–6815 
(2005).
55. Theoharides, T. C., Rozniecki, J. J., Sahagian, G., Jocobson, S., Kempuraj, D., Conti, P., 
Kalomeromitros, D.: Impact of stress and mast cells on brain metastases. J Neuroim-
munol 205, 1–7 (2008).
56. Yurt, R., Austen, K. F.: Preparative purifi cation of the rat mast cell chymase: Charac-
terization and interaction with granule components. J Exp Med 146, 1405–1419 (1977).
57. Schwartz, L. B., Austen, K. F.: Enzymes of mast cell granule. J Invest Dermatol 74, 
349–353 (1980).
58. Welle, M.: Development, signifi cance, and heterogeneity of mast cells with particular 
regard to the mast cell-specifi c proteases chymase and tryptase. J Leukoc Biol 61, 233–
245 (1997).
59. Pejler, G., Rönnberg, E., Waern, I., Wernersson, S.: Mast cell proteases: Multifaceted 
regulators of infl ammatory disease. Blood 115, 4981–4990 (2010).
60. Wernersson, S., Pejler, G.: Mast cell secretory granules: Armed for battle. Nature Rev 
 Immunol 14, 478–494 (2014).
61. Ruoss, S. J., Hartmann, T., Caughey, G. H.: Mast cell tryptase is a mitogen for cultured 
fi broblasts. J Clin Invest 88, 493–499 (1991).
62. Fink, K., Boratynski, J.: The role of metalloproteinases in modifi cation of extracellular 
matrix in invasive tumor growth, metastasis and angiogenesis. Postepy Hig Med Dosw 
66, 609–628 (2012).
63. Woolley, D. E.: Collagenolytic mechanisms in tumor cell invasion. Cancer Metastasis 
Rev 3, 361–372 (1984).
64. Ribatti, D.: Mast cells and macrophages exert benefi cial and detrimental effects on tu-
mor progression and angiogenesis. Immunol Lett 152, 83–88 (2013).
65. Bulfone-Paus, S., Paus, R.: Osteopontin as a new player in mast cell biology. Eur J 
 immunol 38, 338–341 (2008).
66. Oldford, S. A., Haidl, I. D., Howatt, M. A., Leiva, C. A., Johnston, B., Marshall, J. S.: 
A critical role for mast cells and mast cell-derived IL-6 in TRL2-mediated inhibition of 
 tumor growth. J Immunol 185, 7067–7076 (2010).
67. Halova, I., Draberova, L., Draber, P.: Mast cell chemotaxis – Chemoattractants and sign-
aling pathways. Front Immunol 25, 119 (2012)
68. Aoki, M., Pawankar, R., Niimi, Y., Kawana, S.: Mast cells in basal cell carcinoma 
 express VEGF, IL-8 and Rantes. Int Arch Allergy Immunol 130, 216–223 (2003).
69. Katsanos, G. S., Anogeianaki, A., Orso, C., Teté, S., Salini, V., Antinolfi , P. L., Sabatino, 
G.: J Biol Regul Homeost Agents 22, 145–151 (2008).
70. Melillo, R. M., Guarino, V., Galdiero, M. R., Liotti, F., Prevete, N., Rossi, F. W., Basolo, 
F., Ugolini, C., de Paulis, A., Santoro, M., Marone, G.: Mast cells have a protumorigenic 
role in human thyroid cancer. Oncogene 29, 6203–6215 (2010).
71. Ruan, Y., Guan, Y., Wu, Z., Zhang, Z., Zheng, C.: The relationship between RANTES 
and mast cells recruitment in the surroundings of intrahepatic implanted tumors. Clin 
Lab 49, 65–69 (2003).
72. Khazaie, K., Blatner, N. R., Khan, M. W., Gounari, F., Gounaris, E., Dennis, K., Bon-
ertz, A., Tsai, F. N., Struch, M. J., Cheon, E., Philips, J. D., Beckhove, P., Bentrem, D. J.: 
The signifi cant role of mast cells in cancer. Cancer Metastasis Rev 30, 45–60 (2011).
224 CSABA
Acta Microbiologica et Immunologica Hungarica 62, 2015
73. Maltby, S., Khazaie, K., McNagny, K. M.: Mast cells in tumor growth: Angiogenesis, 
tissue remodeling and immune modulation. Biochem Biophys Acta 1796, 19–26 (2009).
74. Boesinger, J., Tsai, M., Maurer, M., Yamaguchi, M., Brown, L. F., Claffey, K. P., Dvorak, 
H. E., Galli, S. J.: Mast cell can secrete vascular permeability factor/vascular endothelial 
growth factor and exhibit enhanced release after immunoglobulin E-dependent upregu-
lation of Fcɛ receptor I expression. J Exp Med 188, 1135–1145 (1998).
75. Ribatti, D., Crivellato, E.: Mast cells, angiogenesis, and tumor growth. Biochem Biophys 
Acta 1822, 2–8 (2012).
76. Lin, T. J., Issekutz, T. B., Marshall, J. S.: SDF1 induces IL-8 production and transen-
dothelial migration of human cord-blood derived mast cells. In Arch Allergy Immunol 
124, 142–145 (2001).
77. Trabucchi, E., Radaelli, E., Marazzi, M., Foschi, D., Musazzi, M., Veronesi, A. M., Mon-
torsi, W.: The role of mast cells in wound healing. Int J Tissue React 10, 367–372.
78. Nienartowicz, A., Sobaniec-Lotowska, M. E., Jarocka-Cyrta, E., Lemancewicz, D.: 
Mast cells in neoangiogenesis. Med Sci Monit 12, RA53–RA56 (2006).
79. Folkman, J., Shing, Y.: Control of angiogenesis by heparin and other sulphated polysac-
charides. Adv Exp Med Biol 313, 355–364 (1992).
80. Folkman, J., Langer, R., Linhardt, R. J., Haudenschild, C., Taylor, S.: Angiogenesis inhi-
bition and tumor regression caused by heparin or a heparin fragment in the presence of 
cortisone. Science 22, 719–725 (1983).
81. Tomita, M., Matsuzaki, Y., Onitsuka, T.: Effect of mast cells on tumor angiogenesis in 
lung cancer. Am Thorac Surg 69, 1686–1690 (2000).
82. Grützkau, A., Krüger-Krasagakes, S., Baumeister, H., Schwarz, C., Kögel, H., Welker, 
P., Lippert, U., Henz, B. M., Möller, A.: Synthesis, storage and release of vascular en-
dothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: 
Implications for the biological signifi cance of VEGF206. Mol Biol Cell 9, 875–884 
(1998).
83. Fraser, R. A., Simpson, J. G.: Role of mast cells in experimental tumour angiogenesis. 
Ciba Found Symp 100, 120–131 (1983).
84. Stockmann, C., Schadendorf, D., Klose, R., Helfrich, I.: The impact of immune system 
on tumor: Angiogenesis and vascular remodeling. Front Oncol 4, 69 (2014).
85. Marech, I., Ammendola, M., Gadaleta, C., Zizzo, N., Oakley, C., Gadaleta, C. D., Rani-
eri, G.: Possible biological and translational signifi cance of mast cells density in colorec-
tal cancer. World J Gastroenterol 20, 8910–8920 (2014).
86. Puxxeddu, I., Piliponsky, A. M., Bachelet, I., Levi-Schaffer, F.: Mast cells in allergy and 
beyond. Int J Biochem Cell Biol 35, 1601–1607 (2003).
87. Weller, K., Foitzik, K., Paus, R., Syska, W., Maurer, M.: Mast cells are required for 
 normal healing of skin wounds in mice. FASEB J 20, 2366–2368 (2006).
88. Noli, C., Miolo, A.: The mast cell in wound healing. Vet Dermatol 12, 303–313 (2001).
89. Younan, G. J., Heit, Y. I., Dastouri, P., Kekhia, H., Xing, W., Gurish, M. F., Orgill, D. P.: 
Mast cells are required in the proliferation and remodeling phases of microdeforma-
tional wound therapy. Plast Reconstr Surg 128, 649e–658e (2011).
90. Weller, C. L., Collington, S. J., Williams, T., Lamb, J. R.: Mast cells in health and  disease. 
Clin Sci 120, 473–484 (2011).
91. Egozi, E. I., Ferreira, A. M., Burns, A. L., Gamelli, R. L., Dipietro, L. A.: Mast cells 
modulate the infl ammatory but not the proliferative response in healing wounds. Wound 
Repair Regen 11, 46–54 (2003).
 MAST CELL: A HOMEOSTATIC ASPECT 225
Acta Microbiologica et Immunologica Hungarica 62, 2015
92. Wuff, B. C., Parent, A. E., Meleski, M. A., DiPietro, L. A., Schrementi, M. E., Wilgus, 
T. A.: Mast cells contribute to scar formation during fetal wound healing. J Invest Der-
matol 132, 458–465 (2012).
93. Oskeritzian, C. A.: Mast cells and wound healing. Adv Wound Care 1, 23–28 (2012).
94. Kennelly, R., Conneely, J. B., Bouchier-Hayes D., Winter, D. C.: Mast cells in tissue 
healing: From skin to the gastrointestinal tract. Curr Pharm Des 17, 3772–3775 (2011).
95. Artuc, M., Hermes, B., Steckelings, U. M., Grützkau, A., Henz, B. M.: Mast cells and 
their mediators in cutaneous wound healing – Active participants or innocent bystand-
ers? Exp Dermatol 9, 1–16 (1999).
96. Lunderius-Andersson, C., Enoksson, M., Nilsson, G.: Mast cells respond to cell injury 
through the recognition of IL-33. Front Immunol 3, 82 (2012).
97. Douaiher, J., Succar, J., Lancerotto, L., Gurish, M. F., Orgill, D. P., Hamilton, M. J., 
Krilis, S. A., Stevens, R. L.: Development of mast cells and importance of their tryptase 
and chymase serine proteases in infl ammation and wound healing. Adv Immunol 122, 
211–252 (2014).
98. Csaba, G.: The immune endocrine system. A new endocrine theory: The problem of the 
packed transport. Orv Hetil 152, 777–784 (2011).
99. Abdel-Majid, R. M., Marshall, J. S.: Prostaglandin E2 induces degranulation-independ-
ent production of vascular endothelial growth factor by human mast cells. J Immunol 
172, 1227–1236 (2004).
100. Csaba, G., Kovács, P.: Hormones in the nucleus of mast cells: Confocal microscopic im-
munocytochemical observations. Horm Metab Res 41, 621–625 (2009).
101. Csaba, G., Pállinger, É.: Gender dependence in the hormone content of the immune 
cells. Acta Physiol Hung 96, 45–50 (2009).
102. Csaba, G., Kovács, P., Pállinger, É.: Effect of a single neonatal endorphin treatment on 
the hormone content of adult rat white blood cells and mast cells. Cell Biol Int 27, 423–
427 (2003).
103. Csaba, G., Kovács, P., Pállinger, É.: Immunologically demonstrable hormones and hor-
mone-like molecules in rat white blood cells and mast cells. Cell Biol Int 28, 487–490 
(2004).
104. Kempuraj, D., Papadopoulou, N. G., Lytinas, M., Huang, M., Kandere-Grzybowska, K., 
Madhappan, B., Boucher, W., Christodoulou, S., Athanassiou, A., Theoharides, T. C.: 
Corticotropin-releasing hormone and its structurally related urocortin are synthesized 
and secreted by human mast cells. Endocrinology 145, 43–48 (2004).
105. Martynova, M. G., Bystrova, O. A., Moiseeva, O. M., Evdorin, A. L., Kondratov, K. A., 
Medvedeva, N. D.: The presence of ANP in rat peritoneal mast cells. Cell Res 15, 811–
816 (2005).
106. Tanaka, A., Nomura, Y., Matsuda, A., Ohmori, K., Matsuda, H.: Mast cells function as 
an alternative modulator of adipogenesis through 15-deoxy-delta-12, 14-prostaglandin 
J2. Am J Physiol Cell Physiol 301, C1360–C1367 (2011).
107. Anand, P., Singh, B., Jaggi, A. S., Singh, N.: Mast cells: An expanding pathophysiologi-
cal role from allergy to other disorders. Naunyn Schmiedebergs Arch Pharmacol 385, 
657–670 (2012).
108. Maldonado, M. D., Mora-Santos, M., Naji, L., Carrascosa-Salmoral, M. P., Naranjo, M. 
C., Calvo, J. R.: Evidence of melatonin synthesis and release by mast cells. Possible 
modulatory role on infl ammation. Pharmacol Res 62, 282–287 (2010).
226 CSABA
Acta Microbiologica et Immunologica Hungarica 62, 2015
109. Csaba, G., Kovács, P., Pállinger, É.: Hormones in the nucleus: Immunologically demon-
strable biogenic amines (serotonin, histamine) in the nucleus of rat peritoneal mast cells. 
Life Sci 78, 1871–1877 (2006).
110. Nakazawa, S., Sakanaka, M., Furuta, K., Natsuhara, M., Takano, H., Tsuchiya, S., 
 Okuno, Y., Ohtsu, H., Nishibori, M., Thurmond, R. L., Hirasawa, N., Nakayama, K., 
Ichikawa, A., Sugimoto, Y., Tanaka, S.: Histamine synthesis is required for granule 
 maturation in murine mast cells. Eur J Immunol 44, 204–214 (2014).
111. Ohtsu, H., Tanaka, S., Terui, T., Hori, Y., Makabe-Kobayashi, Y., Pejler, G., Tchougou-
nova, E., Hellman L., Gertsenstein, M., Hirasawa, N., Sakurai, E., Buzás, E., Kovács, P., 
Csaba, G., Kittel, A., Okada, M., Hara, M., Mar, L., Numayama-Tsuruta, K., Ishigaki-
Suzuki, S., Ohuchi, K., Ichikawa, A., Falus, A., Watanabe, T., Nagy, A.: Mice lacking 
histidine decarboxylase exhibit abnormal mast cells. FEBS Lett 502, 53–56 (2001).
112. Csaba, G., Kovács, P., Buzás, E., Mazán, M., Pállinger, É.: Histidine decarboxylase 
(HDC) knock out mouse immune cells have altered expression of ACTH, triiodothyro-
nine and endorphin. Infl amm Res 56, 428–431 (2007).
113. Iwamura, T., Shimizu, K., Tanaka, S.: Morphological and histochemical characteristics 
of mast cells and the content of in-tissue histamin in various pathological parathyroids: 
Do mast cells participate in hormone secretion in human parathyroids? J Nippon Med 
Sch 69, 347–354 (2002).
114. Csaba, G.: Immunoendocrinology: Faulty hormonal imprinting in the immune system. 
Acta Microbiol Immunol Hung 61, 89–106 (2014).
115. Csaba, G., Kovács, P., Pállinger, É.: Effect of endorphin exposure at weaning on the 
 endorphin and serotonin content of white blood cells and mast cells in adult rat. Cell 
Biochem Funct 22, 197–200 (2004).
116. Csaba, G., Pállinger, É.: Thyrotropic hormone (TSH) regulation of triiodothyronine (T3) 
concentration in immune cells. Infl amm Res 58, 151–154 (2009).
117. Siebler, T., Robson, H., Bromley, M., Stevens, D. A., Shalet, S. M., Williams, G. R.: 
Thyroid status affects number and localization of thyroid hormone receptor expressing 
mast cells in bone marrow. Bone 30, 259–266 (2002).
118. Catini, C., Legnaioli, M.: Role of mast cells in health: Daily rhytmic variations in their 
number, exocytotic activity, histamine and serotonin content in the rat thyroid gland. 
Eur J Histochem 36, 501–516 (1992).
119. Csaba, G., Dunay, C., Fischer, J., Bodoky, M.: Hormonal relationships of mastocytogen-
esis in lymphatic organs. 3. Effect of pineal body-thyroid-thymus system on mast cell 
production. Acta Anat 71, 565–580 (1968).
120. Csaba, G., Bodoky, M., Törő, I.: Hormonal relationships of mastocytogenesis in lym-
phatic organs. II. Effect of epiphysectomy on the genesis of mast cells. Acta Anat 61, 
289–296 (1965).
121. Csaba, G., Baráth, P.: Effect of pinealectomy on the 3H-5HT uptake of mast cells in the 
thyroid gland of the rat. Acta Anat 89, 442–451 (1974).
122. Maslinska, D., Laure-Kamionowska, D., Deregowski, K., Maslinski, S.: Association of 
mast cells with calcifi cation in the human pineal gland. Folia Neuropathol 48, 276–282 
(2010).
123. Krishnaswamy, G., Kelley, J., Johnson, D., Youngberg, G., Stone, W., Huang, S. K., Bie-
ber, J., Chi, D. S.: The human mast cell: Functions in physiology and disease. Front Bi-
osci 6, 1109–1127 (2001).
 MAST CELL: A HOMEOSTATIC ASPECT 227
Acta Microbiologica et Immunologica Hungarica 62, 2015
124. Yoshikawa, H., Tasaka, K.: Suppression of mast cell activation by glucocorticoid. Arch 
Immunol Ther Exp 48, 487–495 (2000).
125. Diaz, B., Barreto, E., Cordeiro, R., Perretti, M., Martins, M., Silva, P.: Enhanced serum 
glucocorticoid levels mediate the reduction of serosal mast cell numbers in diabetic rats. 
Life Sci 68, 2925–2932 (2001).
126. Csaba, G., Dunay, C., Oláh, I., Törő, I.: Effect of glucocorticoids on the thymus. I. His-
tochemical and electronmicroscopic investigation of mast cell formation. Acta Biol 
Acad Sci Hung 18, 345–361 (1967).
127. Csaba, G., Kiss, J., Dunay, C.: Elective localization of 3H-corticosterone in mast cells. 
Experientia 15, 267–269 (1967).
128. Csaba, G., Oláh, I., Kiss, J., Dunay, C.: The localization of 3H-corticosterone in mast cell 
granules by electron microscopic autoradiography. Experientia 23, 944 (1967).
129. Chen, W., Beck, I., Schober, W., Brockow, K., Effner, R., Buters, J. T., Behrendt, H., 
Ring, J.: Human mast cells express androgen receptors but treatment with testosterone 
exerts no infl uence on IgE-indpendent mast cell degranulation elicited by neuromuscu-
lar blocking agents. Exp Dermatol 19, 302–304 (2010).
130. Vlagoftis, H., Dimitriadou, V., Theoharides, T. C.: Progesterone triggers selective mast 
cell secretion of 5-hydroxytryptamine. Int Arch Allergy Appl Immunol 93, 113–119 
(1990).
131. Zhao, X. J., McKerr, G., Dong, Z., Higgins, C. A., Carson, J., Yang, Z. Q., Hannigan, B. 
M.: Expression of oestrogen and progesterone receptors by mast cells alone, but not 
lymphocytes, macrophages or other immune cells in human upper airways. Thorax 56, 
205–211 (2001).
132. Jensen, F., Woudwyk, M., Teles, A., Woidacki, K., Taran, F., Costa, S., Malfertheiner, S. 
F., Zenclussen, A. C.: Estradiol and progesterone regulate the migration of mast cells 
from the periphery to the uterus and induce their maturation and degranulation. PLoS 
One 5, e14409 (2010).
133. Zierau, O., Zenclussen, A. C., Jensen, F.: Role of female sex hormones, estradiol and 
progesterone, in mast cell behavior. Front Immunol 3, 169 (2012).
134. Vasiadi, M., Kempuraj, D., Boucher, W., Kalogeromitros, D., Theoharides, T. C.: Proges-
terone inhibits mast cell secretion. Int J Immunopathol Pharmacol 19, 787–794 (2006).
135. Susko, I., Mornjakovic, Z.: Effect of pinealectomy on mastocyte count in the thymus of 
the rat. Med Arh 57, 7–8 (2003).
136. Calvo, J. R., Gonzalez-Janes, C., Maldonado, M. D.: The role of melatonin in the cells of 
the innate immunity: A review. J Pineal Res 55, 103–120 (2013).
137. Cao, J., Papadopoulou, N., Kempuraj, D., Boucher, W. S., Sugimoto, K., Cetrulo, C. L., 
Theoharides, T. C.: Human mast cells express corticotropin-releasing hormone (CRH) 
receptors and CRH leads to selective secretion of vascular endothelial growth factor. 
J Immunol 174, 7665–7675 (2005).
138. Jaiswal, K., Krishna, A.: Effects f hormones on the number, distribution and degranula-
tion of mast cells in the ovarian complex of mice. Acta Physiol Hung 84, 183–190 (1996).
139. Irman-Florianc, T., Erjavec, F.: The effect of adrenocorticotropin on histamine and 5-hy-
droxytriptamine secretion from rat mast cells. Agents Actions 14, 454–457 (1984).
140. Rasanen, T.: Different hormonal responses of mast cells in gastric mucosa and dermis 
in the rat. Scand J Gastroenterol 2, 118–123 (1967).
228 CSABA
Acta Microbiologica et Immunologica Hungarica 62, 2015
141. Tsakalos, N. D., Theoharides, T. C., Kops, S. K., Askenase, P. W.: Induction of mast cell 
secretion by parathormone. Biochem Pharmacol 32, 355–360 (1983).
142. Chiapetta, N., Gruber, B.: The role of mast cells in osteoporosis. Semin Arthritis Rheum 
36, 32–36 (2006).
143. Turner, R. T., Iwaniec, U. T., Marley, K., Sibonga, J. D.: The role of mast cells in parathy-
roid bone disease. J Bone Miner Res 25, 1637–1649 (2010).
144. Cavalcher-Macado, S. C., de Lima, W. T., Damazo, A. S., de Frias Carvalho, V., Martins, 
M. A., e Silva, P. M., Sannomiya, P.: Down-regulation of mast cell activation and airway 
reactivity in diabetic rats: role of insulin. Eur Respir 24, 552–558 (2004).
145. Zhang, J., Shi, G. P.: Mast cells and metabolic syndrome. Biochem Biophys Acta, 1822, 
14–20 (2012).
146. Harvima, I. T., Nilsson, G.: Stress, the neuroendocrine system and mast cells: Current 
understanding of their role in psoriasis. Expert Rev Clin Immunol 8, 236–241 (2012).
147. Csaba, G., Tekes, K., Pállinger, É.: Infl uence of perinatal stress on the hormone content 
in immune cells of adult rats: Dominance of ACTH. Horm Metab Res 41, 617–620 
(2009).
148. Kumar, V., Sharma, A.: Mast cells: Emerging sentinel innate immune cells with diverse 
role in immunity. Mol Immunol 48, 14–25 (2010).
149. Matsuguchi, T.: Mast cells as critical effectors of host immune defense against Gram-
negative bacteria. Curr Med Chem 19, 1432–1442 (2012).
150. Purcell, W. M., Hanahoe, T. H.: A novel source of mast cells: The human placenta. 
Agents Actions 33, 8–12 (1991).
151. Garfi eld, R. E., Irani, A. M., Schwartz, L. B., Bytautiene, E., Romero, R.: Structural and 
functional comparison of mast cells in the pregnant versus nonpregnant human uterus. 
Am J Obstet Gynecol 194, 261–267 (2006).
152. Bytautiene, E., Vedernikov, Y. P., Saade, G. R., Romero, G., Garfi eld, R. E.: Endogeneus 
mast cell degranulation modulates cervical contractility in the guinea pig. Am J Obstet 
Gynecol 186, 438–445 (2002).
153. Rudolph, M. I., Reinicke, K., Cruz, M. A., Gallardo, V., Gonzalez, C., Bardisa, L.: Dis-
tribution of mast cells and the effect of their mediators on contractility in human myo-
metrium. Br J Obstet Gynecol 100, 1125–1130 (1993).
154. Bytautiene, E., Vedernikov, Y. P., Saade, G. R., Romero, R., Garfi eld, R. E.: Degranula-
tion of uterine mast cells modifi es contractility of isolated myometrium from pregnant 
women. Am J Obstet Gynecol 191, 1705–1710 (2004).
155. Szelag, A., Merwid-Lad, A., Trocha, M.: Histamine receptors in the female reproductive 
system. Part I. Role of the mast cells and histamine in female reproductive system. Gine-
kol Pol 73, 627–635 (2002).
156. Szelag, A., Merwid-Lad, A., Trocha, M.: Histamine receptors in the female reproductive 
system. Part II. The role of histamine in the placenta, histamine receptors and the uterus 
contractility. Ginekol Pol 73, 636–644 (2002).
157. Marx, L., Arck, P., Kieslich, C., Mittelrechner S., Kapp, M., Dietl, J.: Decidual mast cells 
might be involved in the onset of human fi rst-trimester abortion. Am J Reprod Immunol 
41, 34–40 (1999).
158. Cocchiara, R., Lampiasi, N., Albeggiani, G., Azzolina, A., Bongiovanni, A., Gianaroli, 
L., Di Blasi, F., Geraci, D.: A factor secreted by human embryo stimulates cytokine re-
lease by uterine mast cells. Mol Hum Reprod 2, 781–791 (1996).
 MAST CELL: A HOMEOSTATIC ASPECT 229
Acta Microbiologica et Immunologica Hungarica 62, 2015
159. Woidacki, K., Jensen, F., Zenclussen, A. C.: Mast cells as novel mediators of reproduc-
tive processes. Front Immunol 14, 29 (2013).
160. Varayoud, J., Ramos, J. G., Bosquiazzo, V. L., Munoz-de-Toro, M., Luque, E. H.: Mast 
cells degranulation affects angiogenesis in the rat uterine cervix during pregnancy. 
 Reproduction 127, 379–387 (2004).
161. Poglio, S., De Toni-Costes, F., Arnaud, E., Laharrague, P., Espinosa, E., Casteilla, L., 
Cousin, B.: Adipose tissue as a dedicated reservoir of functional mast cell progenitors. 
Stem Cells 28, 2065–2072 (2010).
162. Ishijamaa, Y., Ohmori, S., Ohneda, K.: Mast cell defi ciency results in the accumulation 
of preadipocytes in adipose tissue in both obese and non-obese mice. FEBS Open Bio 
28, 18–24 (2013).
163. Altintas, M. M., Nayer, B., Walford, E. C., Johnson, K. B., Gaidosh, G., Reiser, J., De la 
Cruz-Munoz, N., Ortega, L. M., Nayer, A.: Leptin defi ciency-induced obesity affects the 
density of mast cells in abdominal fat depots and lymph nodes in mice. Lipids Health Dis 
11, 21 (2012).
164. Shi, M. A., Shi, G. P.: Different roles of mast cells in obesity and diabetes: Lessons from 
experimental animals and humans. Front Immunol 25, 3–7 (2012).
165. Sismanopoulos, N., Delivanis, D. A., Marommati, D., Hatziagelaki, E., Conti, P., Theo-
harides, T. C.: Do mast cells link obesity and asthma? Allergy 68, 8–15 (2013).
166. Marone, G., Casolaro, V., Patella, V., Florio, G., Triggiani, M.: Molecular and cellular 
biology of mast cells. Int Arch Allergy Immunol 114, 207–217 (1997).
167. Roedewald, H. R., Feyerabend, T. B.: Widespread immunological functions of mast 
cells: Fact or fi ction? Immunity 37, 13–24 (2012).
168. He, A., Shi, G. P.: Mast cell chymase and tryptase as targets for cardiovascular and 
metabolic diseases. Curr Pharm Des 19, 1114–1125 (2013).
169. Xu, J. M., Shi, G. P.: Emerging role of mast cells and macrophages in cardiovascular 
and metabolic diseases. Endocr Rev 33, 71–108 (2012).
170. Bot, I., Shi, G. P., Kovanen, P. T.: Mast cells as effectors in atherosclerosis. Arterioscler 
Thromb Vasc Biol 35, 265–271 (2015).
171. Nelson, R. B., Siman, R., Iqbal, M. A., Potter, H.: Identifi cation of chymotrypsin-like 
mast cell protease in rat brain capable of generating the N-terminus of the Alzheimer 
amyloid beta-protein. J. Neurochem 61, 567–577 (1993).
172. Hodges, K., Kennedy, L., Meng, F., Alpini, G., Francis, H.: Mast cells, disease and gas-
trointestinal cancer: A comprehensive review of recent fi ndings. Transl Gastrointest 
Cancer 1, 138–150 (2012).
173. Van Nassauw, L., Adriaensen, D., Timmermans, J. P.: The bidirectional communication 
between neurons and mast cells within the gastrointestinal tract. Auton Neurosci 133, 
91–103 (2007).
174. Tore, F., Tuncel, N.: Mast cells: Target and source of neuropeptides. Curr Pharm Des 15, 
3433–3445 (2009).
175. Csaba, G.: Hormones in the immune system and their possible role. A critical review. 
Acta Microbiol immunol Hung 61, 241–260 (2014).
176. Puzianowska-Kuznicka, M., Pietrzak, M., Turowska, O., Nauman, A.: Thyroid hor-
mones and their receptors in the regulation of cell proliferation. Acta Biochem Pol 53, 
641–650 (2006).
177. Dentice, M., Ambrosio, R., Salvatore, D.: Role of type 3 deiodinase in cancer. Expert 
Opin Ther Targets 13, 1363–1373 (2009).
230 CSABA
Acta Microbiologica et Immunologica Hungarica 62, 2015
178. Csaba, G.: The hormonal system of the unicellular Tetrahymena: A review with evolu-
tionary aspects. Acta Microbiol Immmmunol Hung 59, 131–156 (2012).
179. Csaba, G.: The unicellular Tetrahymena as a model cell for receptor research. Int Rev 
Cytol 95, 327–377 (1985).
180. Csaba, G.: Hormonal imprinting in the unicellular Tetrahymena: The proto-model of 
epigenetics. Acta Microbiol Immunol Hung 59, 291–310 (2012).
181. von Dorsche, H.H., Fehrmann, P., Sulzmann, R.: Die Mastzelle als einzellige endokrine 
Drüse. Acta Anat 77, 560–569 (1970).
182. Cavalcante, M. C., de Andrade, L. R., Du Bocage Santos-Pinto, C., Straus, A. H., Taka-
hashi, H. K., Allodi, S., Pavao, M. S.: Colocalization of heparin and histamine in the 
inracellular granules of test cells from the invertebrate Styela plicata (Chordata-Tuni-
cata). J Struct Biol 137, 313–321 (2002).
183. Wong, G. W., Zhuo, L., Kimata, K., Lam, B. K., Satoh, N., Stevens, R. L.: Ancient origin 
of mast cells. Biochim Biophys Res Com 451, 314–318 (2014).
184. Csaba, G., Kovács, P.: Perinuclear localization of biogenic amines (serotonin and hista-
mine) in rat immune cells. Cell Biol Int 30, 861–865 (2006).
185. Kitamura, Y., Oboki, K., Ito, A.: Development of mast cells. Proc Jpn Acad Ser B Phys 
Biol Sci 83, 164–174 (2007).
186. Csaba, G., Hodinka, L.: The thymus as a source of mast cells in the blood. Acta Biol 
Acad Sci Hung 21, 333–334 (1970).
187. Csaba, G., Törő, I., Bodoky, M.: On the formation of mast cells in the thymus and lym-
phatic organs. Z Mikr Anat Forsch 70, 242–251 (1963).
188. Csaba, G., Hodinka, L., Surján, L. jr.: Transport of mast cells by the blood circulation. 
Experientia 25, 735–736 (263).
189. Csaba, G., Hodinka, L., Bozsóky, S., Farkas, K.: Tissue mast cells in human blood. Pre-
liminary report. Haematologia 4, 415–417 (1970).
190. Csaba, G., Török, O.: Physiology of mast cells. IV. Role of blood transport in the tansfor-
mation of mast cells. Acta Biol Acad Sci Hung 23, 369–376 (1972).
191. Kambe, N., Hiramatsu, H., Shimonaka, M., Fujino, H., Nishikomori, R., Heike, T., 
 Ueyama, Y., Matsuyoshi, N., Miyachi, Y., Nakahata, T.: Development of both human 
connective tissue-type and mucosal-type mast cells in mice from hemopoietic stem cells 
with identical distribution pattern to human body. Blood 103, 860–867 (2004).
192. Csaba, G., Török, O.: Physiology of mast cells. I. Behavior of mast cells in tissue culture. 
Acta Biol Acad Sci Hung 21, 63–744 (1970).
193. Csaba, G.: Mechanism of the formation of mast cell granules. VII. Participation of 
amines and basic proteins in the formation of mast cell granule. Analysis of the hetero-
geneity of mast cells. Acta Biol Acad Sci Hung 22, 155–168 (1971).
194. Csaba, G., Baráth, P.: Heterogeneity of mast cell populations as emerging from studies 
with labelled amines and amine precursors. Acta Biol Acad Sci Hung 25, 323–325 
(1974).
195. Csaba, G.: Mechanism of the formation of mast cell granules. 3. Self-regulating system 
of granule formation. Acta Biol Acad Sci Hung 20, 211–218 (1969).
196. Csaba, G.: Mechanism of the formation of mast cell granules. II. Cell-free model. Acta 
Biol Acad Sci Hung 20, 205–210 (1969).
197. Csaba, G., Surján, L. jr.: Demonstration of histones in the granules of developing mast 
cells induced by biogenic amine. Acta Biol Acad Sci Hung 21, 243–245 (1970).
 MAST CELL: A HOMEOSTATIC ASPECT 231
Acta Microbiologica et Immunologica Hungarica 62, 2015
198. Csaba, G., Surján, L. jr.: Mechanism of the formation of mast cell granules. V. Histo-
chemical detection of histones in the mast cell granules. Acta Biol Acad Sci Hung 21, 
341–346 (1970).
199. Csaba, G., Kapa, E.: Uptake of heparin by cells. Nature 187, 711–713 (1960).
200. Csaba, G.: Regulation of Mast Cell Formation. Academic Press, Budapest, 1972.
201. Rigoni, A., Colombo, M. P., Pucillo, C.: The role of mast cells in molding the tumor mi-
croenvironment. Cancer Microenviron (2014), Epub ahead of print.
202. Papadimitriou, E., Polykratis, A., Hatziapostolou, M., Parthymou, A., Polytarchou, C., 
Mikelias, C.: Heparin affi n regulatory peptide: A new target for tumor therapy? Curr 
Cancer Drug Targets 4, 471–482 (2004).
203. Groot Kormelink, T., Abudukelimu, A., Redegeld, F. A.: Mast cells as target in cancer 
therapy. Curr Pharm Des 15, 1868–1878 (2009).
204. Csaba, G., Ács, T., Horváth, C., Kapa, E.: Some new data concerning the biology of 
 tumours. Br J Cancer 15, 367–375 (1961).
205. Csaba, G., Kőrösi, J.: A new antitumor agent: Phenazathionium-mustard salt. Neo-
plasma 15, 443–445 (1968).
206. Csaba, G., Kiss, J., Kőrösi, J.: Intratumoral localization of phenazathionium-mustard 
chloride: A new antitumor agent. Neoplasma 16, 145–149 (1969).
207. Csaba, G., Mold, K., Kőrösi, J.: On the effect of tumor-inhibiting agents bound to inacti-
vated heparin on tissue cultures. Neoplasma 11, 345–351 (1964).
208. Csaba, G., Kőrösi, J., Horváth, C., Mold, K., Ács, T.: Effect of heparin-bound alkylating 
agents and enzyme inhibitors on neoplastic growth. Neoplasma 11, 137–144 (1964).
209. Németh, L.: Experimental studies on the tumour inhibitory effect of heparin-degranol 
(Zitofenton). Neoplasma 16, 137–143 (1969).
210. Sellei, C.: Chemotherapy of Neoplastic Diseases. Academic Press, Budapest, 1970.
